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Abstract
Introduction: Dysregulated cytokine action on immune cells plays an important role in the initiation and progress of
systemic lupus erythematosus (SLE), a complex autoimmune disease. Comprehensively quantifying basal STATs
phosphorylation and their signaling response to cytokines should help us to better understand the etiology of SLE.
Methods: Phospho-specific flow cytometry was used to measure the basal STAT signaling activation in three immune cell
types of peripheral-blood mononuclear cells from 20 lupus patients, 9 rheumatoid arthritis (RA) patients and 13 healthy
donors (HDs). A panel of 27 cytokines, including inflammatory cytokines, was measured with Bio-Plex
TM Human Cytokine
Assays. Serum Prolactin levels were measured with an immunoradiometric assay. STAT signaling responses to inflammatory
cytokines (interferon a [IFNa], IFNc, interleukin 2 [IL2], IL6, and IL10) were also monitored.
Results: We observed the basal activation of STAT3 in SLE T cells and monocytes, and the basal activation of STAT5 in SLE T
cells and B cells. The SLE samples clustered into two main groups, which were associated with the SLE Disease Activity Index
2000, their erythrocyte sedimentation rate, and their hydroxychloroquine use. The phosphorylation of STAT5 in B cells was
associated with cytokines IL2, granulocyte colony-stimulating factor (G-CSF), and IFNc, whereas serum prolactin affected
STAT5 activation in T cells. The responses of STAT1, STAT3, and STAT5 to IFNa were greatly reduced in SLE T cells, B cells,
and monocytes, except for the STAT1 response to IFNa in monocytes. The response of STAT3 to IL6 was reduced in SLE T
cells.
Conclusions: The basal activation of STATs signaling and reduced response to cytokines may be helpful us to identify the
activity and severity of SLE.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease
of unknown etiology. Dysregulated cytokine release plays an
important role in the etiology of SLE and also correlates with its
progression. Inflammatory cytokines, such as interleukin 6 (IL6,)
IL10, interferon a (IFNa), and IL12, are elevated in the sera of
SLE patients [1–3]. Jak-STAT [the activation of the Janus kinases
(Jaks) and their downstream signal transducer and activator of
transcription (Stat) proteins] signaling play a critical role in
mediating the biological response to most of these cytokines.
When cytokines bind their specific receptors, the JAKs are
activated by phosphorylating specific receptor tyrosine motifs.
STATs are then activated by the JAK-dependent tyrosine phos-
phorylation. Activated STATs finally translocate to the nucleus,
start the transcription of genes related [4–5].
The abnormal of STAT signaling pathway in immune cells
of SLE has been reported before. T cells from patients with SLE
display increased levels of total and phosphorylated STAT3, which
is located primarily in the nucleus [6]. Elevated total STAT1
protein or its activated/phosphorylated form have also been
detected in kidney samples from patients with diffuse proliferative
lupus nephritis (DPLN) and MRL/lpr mice with lupus nephritis
[7–8]. STAT-1 expression was also be found increased in
peripheral-blood mononuclear cells (PBMC)from SLE patients
and correlated significantly with disease activity. SLE monocytes
showed a considerably higher increase in pSTAT-1 expression
upon IFNc stimulation than monocytes from healthy individuals
[9].
However, little is known about the profiles of phosphorylated
STATs (pSTATs) in the PBMC of SLE patients. Measuring
pSTATs levels in immune cell subtypes should extend our
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21671understanding of the JAK–STAT signaling network in the etiology
of SLE as well as in other disease such as cancer [10–11] and in
human immunodeficiency virus (HIV) infection [12]. The tech-
nique of phospho-specific flow cytometry measures the phosphor-
ylation state of intracellular proteins at the single cell level has been
verified as a rapid and reliable tool for measuring intracellular
signaling proteins at the single cell level [13–17].
Here we applied phospho-specific flow cytometry to measure
the basal STATs phosphorylation and their signaling response in




Ethics approval for this study was obtained from the Ethics
Committee of Shanghai Renji Hospital, Shanghai Jiaotong
University School of Medicine.
Subjects
We recruited 20 lupus patients, 9 RA (rheumatoid arthritis), 13
normal controls, after obtaining their informed consent. Partici-
pants with a current or recent infection were excluded from the
study (Table 1). All SLE and RA patients fulfilled the American
College of Rheumatology classification criteria for SLE [18] and
RA [19]. The SLE Disease Activity Index 2000 (SLEDAI-2K)
score for each patient was determined at the time of blood
collection [20] (Table 1). The average prednisone dose taken by all
the SLE patients was 17.38 mg/day, one patient had not been
treated with immunosuppressants, four patients were not receiving
steroid therapy, eight patients were receiving an antimalarial drug
(hydrochloroquine 200–400 mg/day), and three patients were
taking 5–7.5 mg of methotrexate per week. No patient was using
another immunosuppressant, such as mycophenolate mofetil,
cyclophosphamide, or cyclosporin A. None of the RA patients
received steroid therapy. The patients were taking 7.5–15 mg of
methotrexate per week. No patient was using biologic agents or
lefluomide.
Antibodies and flow cytometry
The following antibodies were used in this study, and were
purchased from BD PharMingen (San Diego, CA): anti-pStat1
(pY701), anti-pStat3(pY705), anti-pStat5(pY694), anti-CD3, anti-
CD14, and anti-CD19. Lyse/Fix Buffer, Perm Buffer II, and
Staining Buffer (FBS) were also purchased from BD PharMingen.
For the ex vivo stimulation experiments, fresh PBMC were
cultured in complete RPMI 1640 medium (Gibco, Invitrogen,
Carlsbad, CA, USA) containing 10% fetal calf serum (FCS),
100 U/mL penicillin (Gibco), and 100 mg/mL streptomycin
(Gibco). The PBMC were stimulated for 15 min with 500 U/
mL IFNa, 10 ng/mL IFNc, 50 U/mL IL2, 200 ng/mL IL6, or
10 ng/mL IL10. The PBMC were then fixed in Lyse/Fix Buffer at
37uC for 15 min.
The staining experiments were performed according to the
manufacturer’s protocol. In brief, human PBMC, unstimulated or
stimulated with the cytokines cited above, were fixed in Lyse/Fix
Buffer (BD Biosciences) at 37uC for 15 min, and washed once with
2% FCS. The PBMC were permeabilized with cold Perm Buffer II
for 30 min on ice, washed once with phosphate-buffered saline,
then stained with primary antibody for 30 min, and washed twice
with 2% FCS before analysis. The data were analyzed using
CellQuest software (BD Biosciences, Mountain View, CA).
Cytokine measurements
Blood samples were taken from the patients and healthy donors
(HDs) after an overnight fast. Hemolyzed samples were discarded.
We measured IL1b, IL1 receptor a (IL1ra), IL2, IL4, IL5, IL6,
IL7, IL8, IL10, IL12(p70), IL13, IL15, IL17, basic fibroblast
growth factor, eotaxin, granulocyte colony-stimulating factor (G-
CSF), granulocyte–macrophage colony-stimulating factor (GM-
CSF), interferon c (IFNc), monocyte chemotactic protein 1,
macrophage inflammatory proteins 1a (MIP1a), MIP1b, human
platelet-derived growth factor BB, RANTES (regulated upon
activation of normal T cell expressed and secreted), tumor necrosis
factor a (TNFa), and vascular endothelial growth factor using
Bio-Plex
TM Human Cytokine Assays (27-Plex panel; Bio-Rad,
Hercules, CA). The samples were analyzed with the Bio-Plex
Manager Software (Bio-Rad). Prolactin (PRL) levels were assessed
with a chemiluminescent assay (Immulite/Immulite 1000 n, Siemens
Medical Solutions Diagnostics). The cytokines were measured in a
single well.
Statistical analysis
The data were analyzed using the Prism4 software, version 4.03
(GraphPad, CA, USA). An Unpaired Student’s t-tests were used,
provided that the data followed Gaussian distributions. Mann-
Whitney tests were used when the data were not normally
distributed. Pearson and Spearman correlation coefficients were
used for correlation studies between variables that were or were
not normally distributed. P values less than 0.05 were considered
significant. SLE samples were clustered using the HCE3.5 package
(Hierarchical Cluster Explorer) [21].
Results
Activation of STAT signaling in SLE patients
Peripheral anticoagulated blood cells were lysed, fixed, and
stained with antibodies specific for the surface markers CD3,
CD14, and CD19. The phosphorylation of STAT1, STAT3, and
STAT5 on the activating residues was measured and compared in
three subsets of immune cells (CD3
+ T cells, CD19
+ B cells, and
CD14
+ monocytes) in 20 SLE patients, 9 RA patients and 13 HDs
(Figure 1A). The SLE patients, RA patients and HDs did not differ
significantly with respect to their mean ages or sex distributions
(Table 1). The mean SLEDAI-2K score of 7.35 indicates that the
SLE patients had moderate disease activity (Table 1). The median
fluorescence intensity (MFI) for each pSTAT in the SLE, RA
patients was calculated and compared with that of the HDs.
Increased activation of STAT3 was observed in SLE, RA T
cells (SLE 3.58460.1243, RA 3.62060.2553, HD 3.03460.1026,
SLE vs HD, P,0.01, RA vs HD P,0.05, Figure 1A, Revised
Table 1. Demographics of SLE and RA patients and healthy
donors.
SLE patients (n=20) RA (n=9) HDs (n=13)
Age (years) 33.7562.558 33.7863.479 27.9260.4995
Sex, female (%) 17 (85%) 1 (88.89%) 11 (84.62%)
Disease duration (years) 5.31961.502 4.88961.701 _
SLEDAI-2K 7.35066.714 _ _
Except where otherwise indicated, the values expressed are means 6 standard
errors of the means (ranges). There were no significant differences between the
patients with SLE, the patients with RA, and the healthy donors in terms of their
age and sex. SLE, systemic lupus erythematosus; RA, rheumatoid arthritis;
SLEDAI-2K, SLE Disease Activity Index 2000; HDs, healthy donors.
doi:10.1371/journal.pone.0021671.t001
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of STAT3 than disease control RA and healthy donors. The
expression level of phosphorylation of STAT3 in Monocytes of RA
showed lower than SLE and HD (SLE 10.2560.5551, RA
6.94660.4587, HD 8.64860.3694, SLE vs HD P,0.05, SLE vs
RA, P,0.01, RA vs HD, P,0.01, Figure 1B, Revised Figure 2B).
Increased activation of STAT5 was observed in SLE, RA B
cells and T cells. (B cells: SLE 4.83760.2955, RA 4.94560.2672,
HD 3.86660.1453, SLE vs HD P,0.05, RA vs HD P,0.01,
Figure 1C, Revised 2C; T cells: SLE 5.88960.2864, RA 4.774
60.4005, HD 3.03460.1026, SLE vs HD, P,0.001, RA vs HD
P,0.01, Figure 1D, Revised Figure 2D). The expression level of
phosphorylation of STAT5 in T cells showed lower in RA than
SLE (P,0.05, Revised Figure 2D). Our data indicated the
activation of STAT3, STAT5 signaling in PBMC of SLE patients.
There existed disease-specific profiling of PBMC pSTATs. There
was activation of STAT3 in the monocytes of SLE patients, but
this STAT3 signaling was inhibited in the monocytes of RA
patients (Revised Figure 2B).
No STAT1 activation was detected in any of the three major
immune-cell types.
Activation of basal STAT signaling is associated with SLE
activity
The basal STAT signaling transduction varied significantly
within one SLE patient, and between the SLE patient samples.
The activation of STAT3 was increased in SLE T cells and
monocytes, as was the activation of STAT5 in SLE T cells and B
cells, relative to that in HDs. STAT signaling increased in some
patients but decreased or disappeared in others. For example, SLE
patient 10 showed STAT5 activation in his B cells and T cells, but
lower pSTAT3 was detected in his T cells and monocytes. In SLE
patient 01, STAT5 was activated in his T cells, but the phos-
phorylation of STAT5 was lower in his B cells, and pSTAT3 was
reduced in his T cells and monocytes (Figure 3).
The SLE patients were further clustered with the HCE3.5
package (Hierarchical Cluster Explorer), according to the basal
activation of the STAT3 in their mononuclear cells and T cells,
and of STAT5 in their B cells and T cells. Each grid represents
the phosphorylation of a STAT protein in one cell type. The
phosphorylation of each STAT protein was scaled relative to the
minimum phosphorylation level among the 20 SLE samples.
Unsupervised clustering identified two main groups of SLE
patients (Figure 3). The patients of group 1 were primarily defined
by potentiated STAT5 signaling in their T cells and B cells,
whereas there was no detectable activation of STAT5 in the B cells
of the patients in group 2.
To investigate whether the phospho-profiling of STAT proteins
might be related to lupus activity, we compared the clinical
manifestations of the two groups identified with hierarchical
clustering (Table 2). SLEDAI-2K and the erythrocyte sedimenta-
tion rate (ESR) were higher in the patients of group 2 (9.4446
1.98 and 45.4368.96 mm/h, respectively) than those in group 1
(4.36460.9271 and 1663.613 mm/h, respectively) (P=0.0237 and
Figure 1. pSTATs expression in SLE patient and healthy donor (HD). A representative experiment is shown. The MFI of pSTAT3 in the T cells
(1A), monocytes (1B) of SLE patient was compared with that of HD. The MFI of pSTAT5 in the B cells (1C), T cells (1D) of SLE patient was compared
with that of HD. MFI, mean fluorescence index; SLE, systemic lupus erythematosus; HD, healthy donor.
doi:10.1371/journal.pone.0021671.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e21671Figure 2. Comparison of pSTATs expression between SLE, RA patients and healthy donors (HDs). Each symbol represents an individual
patient or HDs. (A) The MFI of pSTAT3 was elevated in the T cells of SLE, RA patients relative to that in HDs. (B) The MFI of pSTAT3 was elevated in the
monocytes of SLE patients, but decreased in the monocytes of RA as compared with that in HDs. (C) The B cells of SLE patients, RA patients showed a
higher MFI for pSTAT5 than that in HDs. (D) The T cells of SLE patients, RA patients showed a higher MFI for pSTAT5 than that in HDs. MFI, mean
fluorescence index; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis;HDs, healthy donors.
doi:10.1371/journal.pone.0021671.g002
Figure 3. SLE samples were clustered by the expression of basal phosphorylated STAT3 and STAT5. Each grid represents the
phosphorylation of a STAT protein in one cell type. The phosphorylation of each STAT protein was scaled relative to the minimum phosphorylation
level among the 20 SLE samples.The 20 SLE patient samples were grouped according to their similarities using hierarchical clustering. Two groups of
SLE patients were identified, based on similarities in the expression of basal phosphorylated STAT3 and STAT5 in specific cell types. HCQ use and the
mean disease activity index (SLEDAI)-2K of each group are indicated at the bottom. SLE, systemic lupus erythematosus;HCQ, hydroxychloroquine.
doi:10.1371/journal.pone.0021671.g003
STAT Phosphorylation Profiling for SLE Activity
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e21671P=0.0052, respectively). The patients in group 2 had lower C3
levels than those of group 1, but this difference was not significant.
No significant differences was found in either the clinical mani-
festations, such as rash, arthritis, vasculitis, oral ulcers, proteinuria,
white blood cells, and hemoglobin, or the autoantibody profiles,
including anti-Ro, anti-U1 RNP, anti-Sm, and anti-dsDNA, of the
two groups. There was no statistically significant difference in the
prednisone doses of the two groups. Hydroxychloroquine (HCQ)
was used more commonly by group 1 patients than by group 2
patients (P=0.0281; Figure 3, Table 2).
To determine whether the activation of basal STAT signaling
varies over time and parallels SLE activity, the cell-specific
phosphorylation of STATs in four SLE patients with active lupus
were re-analyzed after clinical remission. There was a positive
correlation between STAT5 activity and lupus activity as assessed
by SLEDAI-2K (Figure 4).
STAT5 signaling in B cells is associated with inflammatory
cytokines
STAT5 activation in B cells correlated with the activity of SLE,
as estimated as SLEDAI-2K. We then asked whether the inflam-
matory cytokines influence STAT5 signaling in lupus patients.
A panel of 27 cytokines was detected in the sera of SLE patients
using Bio-Plex
TM Cytokine Assays. A series of cytokines, including
IL2 (P=0.0015, r
2=0.44 ; Figure 5A), IFNc (P=0.0011, r
2=
0.45; Figure 5B), and G-CSF (P=0.0046, r
2=0.37; Figure 5C)
were all correlated positively with STAT5 phosphorylation in B
cells.
Phosphorylation of Stat5 in T cells is associated with
serum prolactin
PRL–STAT5 signaling was observed in the pathogenesis of
cancer, including breast cancer [22–25]. In this study, we found
high STAT5 activity in the T cells and B cells of SLE patients. To
identify whether serum PRL levels are associated with the activa-
tion of STAT5 signaling in T and B cells, we compared the
percentage of T cells and B cells with STAT5 activity and serum
PRL levels. The percentage of T cells with phosphorylated
STAT5 correlated positively with serum PRL (r
2=0.33, P=
0.0009; Figure 5D).
Table 2. Comparison of SLE patients in the two clusters.
Variable Group 1 (n=11) Group 2 (n=9) P Value
Disease duration, years 4.42561.543 6.41262.827 NS
Rash 6 (54.54%) 5 (55.55%) NS
Arthritis 0 0 NS
Vasculitis 2 (18.18%) 1 (11.11%) NS
Oral ulcers 0 0 NS
Proteinuria 2 (18.18%) 2 (22.22%) NS
SLEDAI-2K{ 4.36460.9271 9.44461.98 0.0237
ESR, mm/h{ 1663.613 45.4368.96 0.0052
C3, mg/dL 0.760960.06341 0.625660.05771 NS
Low complement 4 (36.36%) 7 (77.78%) NS
WBC 0 1 (11.11%) NS
Hgb 2 (18.18%) 0 NS
Autoantibody profile
Anti-Ro NS 2 (22.22%) NS
Anti-U1 RNP 0.0281 2 (22.22%) NS
Anti-Sm 4 (36.36%) 2 (22.22%) NS
Anti-dsDNA 4 (36.36%) 6 (66.67%) NS
No. autoantibodies¥ 1.36460.0643 1.55660.4120 NS
Medical therapy
Immunosuppressants 8 (72.72%) 2 (22.22%) NS
Prednisone dose, mg/day
1 17.5063.873 17.265.535 NS
HCQ 7 (63.64%) 1 (11.11%) 0.0281
Values presented are means 6 SD or numbers (%) of patients, depending on
whether the data are continuous or dichotomous. ESR=erythrocyte
sedimentation rate; Hgb=hemoglobin; dsDNA=double-stranded DNA;
HCQ=hydroxychloroquine; NS=not significant.
{Mann–Whitney test was used, instead of a t test, because the data were not
normally distributed.
¥Autoantibodies included anti-dsDNA, anti-Ro, anti-La, anti-U1 RNP, and anti-
Sm antibodies, with a range of 0–5.
1All glucocorticoid doses were converted to equivalent daily doses of
prednisone.
doi:10.1371/journal.pone.0021671.t002
Figure 4. Phosphorylation of STAT5 was observed in patients at the beginning and after treatment. The expression of phosphorylated
STAT5 in B cells was notably reduced in patients who had achieved significant clinical improvement after treatment. SLE-04, SLE-05, SLE-10, and SLE-
12 represent four different patients.
doi:10.1371/journal.pone.0021671.g004
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cytokines
Most cytokines activate STAT proteins that are phosphorylated
at certain residues when they combined with specific surface
receptors on the immune cells. We found basal levels of STAT3
and STAT5 signaling activation in SLE patients. Quantifying the
cell-type-specific STAT signaling responses to cytokines should
help us to better understand the pathology of SLE. PBMC were
stimulated ex vivo with the inflammatory cytokines IFNa, IFNc,
IL2, IL6, and IL10, which are reported to play a role in the
pathogenesis of SLE. Cytokine-induced fold changes in STAT
phosphorylation were compared with those of HDs.
In general, there was a reduced signaling response to certain
cytokines in SLE patients compared with those in HDs. The
responses of STAT1, STAT3, and STAT5 to IFNa were greatly
reduced in SLE T cells, B cells, and monocytes, except for the
activation of STAT1 in monocytes. The STAT3 response to IL6
was reduced in SLE T cells. Although there was enhanced
responsiveness to IL10, but this difference in SLE patients was not
statistically significant (Figure 6, Figure 7).
Discussion
Cytokine network dysregulation is highly complex in SLE,
Here, we focused on JAK–STAT signaling,which is one of the
main intracellular signaling pathways activated by cytokines. The
activation of STAT3 was observed in the monocytes and T cells of
SLE patients, which was consistent with previous findings that
SLE T cells exhibited higher levels of STAT3 and phosphorylated
STAT3 [26]. Karonitsch T et.al found that STAT-1 expression
was increased in PBMCs from SLE patients, SLE monocytes
showed a considerably higher increase in pSTAT-1 expression
upon IFNc stimulation than monocytes from healthy individuals
[9]. But we did not find the same result. One of the reason may be
caused by heterogeneity of the SLE patients such as the genetic
background of SLE patients, for all of our patients were Chinese.
We also need increase our sample number to further confirm this
phenomenon.
STAT5 signaling is also activated in lupus patients. In this
study, STAT5 phosphorylation was much higher in group 2 SLE
patients than in group 1 patients, which were segregated by
clustering analysis, and the patients in group 2 were also confirmed
as having more disease activity evaluated using the SLEDAI-2K
and ESR than group 1 (Figure 2). The MFI of phosphorylation of
STAT5 in B cells of PBMC significantly reduced when disease
going into remission, which indicated that the STAT5 signaling in
B cells also correlated with the disease status (Figure 3).
STAT5 is known to be activated by a wide range of cytokines,
including the common c-chain (cc) family, the IL3 family, single-
chain receptors, class II receptors, and growth factors [27]. We
then asked whether these cytokines influence STAT5 signaling in
SLE. A cytokine panel was detected in the sera of SLE patients,
and we found that cytokines of the common c-chain (cc) family
(including IL2), the IL3 family (including G-CSF), and class II
receptors (including IFNc) all correlated with STAT5 phosphor-
ylation in B cells (Figure 5). All these cytokines were elevated in
Figure 5. Association between the mean fluorescence index (MFI) of pSTAT5 in B cells and cytokine levels in SLE patients. The
concentrations of serum IL2 (A), IFNc (B) and G-CSF (C),correlated positively with the MFI of STAT5 in the B cells of SLE patients. (D) The serum
prolactin concentration correlated positively with the MFI of pSTAT5 in the T cells of SLE patients. MFI, mean fluorescence index; IL, interleukin; IFNc,
interferon c; G-CSF, granulocyte colony-stimulating factor; PRL, prolactin.
doi:10.1371/journal.pone.0021671.g005
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patients with active disease (data not shown).
There was no correlation between the phosphorylation of
STAT5 in T cells and lupus disease activity or cytokine secre-
tion. Hyperprolactinemia has been confirmed in SLE patients
(20%–30%), and those with active SLE display higher serum PRL
levels. PRL activates STAT5 when it binds to the prolactin
receptor and induces immunoglobulin synthesis and anti-dsDNA
in SLE lymphocytes [28–30]. Our study indicates that PRL–
STAT5 signaling is cell-type specific, and only influences T cells,
but not B cells or not monocytes.
The STAT5 signaling in T cell and B cells may provided as new
therapy target in future such as inhibition the phosphorylation of
STAT5, its cytokine receptors or other molecules of STAT5 signal
pathway. Decrease the prolactin in the serum will be another
treatment target in SLE. Bromocriptine, a dopamine analog, has
been suggested be beneficial in protecting the SLE patients from
disease relapse and in reducing the usage of steroid and immuno-
suppressant by suppressing the circulating prolactin [31–33]. Our
results showed the therapeutic mechanism of the bromocriptine in
SLE and will help us to expand the use of bromocriptine in SLE.
Strong negative regulation of the signaling response to the
cytokines IFNa and IL6 was also observed, which has a causal role
in human SLE. This result is consistent with the observation of
Hale et al. in an lpr mouse model of lupus [16].
Hydroxychloroquine were used more frequently by the pa-
tients in group 1 than by those in group 2. Chloroquine, an
antimalarial agent, is a drug commonly used in the treatment of
SLE. A previous study showed that chloroquine can inhibit
lymphocyte proliferation. Our results show that hydroxychloro-
quine might exert its antiproliferative effect by inhibiting JAK–
STAT signaling.
In summary, basal activation of STAT signaling and a reduced
response to the cytokines IFNa and IL6 were observed in the
peripheral blood of SLE patients. The phosphorylation of STAT5
is associated with cytokines such as PRL, IL2, G-CSF, and IFNc,
which exert their biological effects through cytokine receptors and
cell-type specifically. STAT5 signaling is very important in the
regulation of the immune response in SLE. The basal activation of
STATs signaling and reduced response to cytokines may be
helpful us to identify the activity and severity of SLE although
larger sample numbers still need to further confirm our result.
Figure 6. Comparison pSTATs expression between SLE patient and healthy donor (HD) after cytokine stimulation. A representative
experiment is shown. The MFI for the phosphorylation of STAT1 (5A), STAT3 (5B), and STAT5 (5C) in the T cells of SLE patient was compared with that
of HD. The MFI for the phosphorylation of STAT1 (5D), STAT3 (5E), and STAT5 (5F) in the B cells of SLE patient was compared with that of HD. The MFI
for the phosphorylation of STAT3 (5G) and STAT5 (5H) in the monocytes of SLE was compared with that of HD. The MFI for pSTAT3 (5I) in the T cells of
SLE patient was compared with that of HD. MFI, mean fluorescence index; SLE, systemic lupus erythematosus; HD, healthy donor; IFNa, interferon a.
doi:10.1371/journal.pone.0021671.g006
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